Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Part A:
ensovibep: Route: Intravenous
Dose: 10 mL vials are used containing 15 mg/mL ensovibep provided in isotonic buffer matrix.
Patients in Part A will be assigned on Day 1 at Visit
Sponsors
Molecular Partners AG
IQVIA RDSIndia Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Patients eligible for inclusion in this study must meet all the following criteria: 1. Men or women >= 18 years of age on the day of inclusion (no upper limit). 2. Presence of two or more of the following COVID-19 symptoms with an onset within 7 days of dosing: Feeling hot or feverish, cough, sore throat, low energy, or tiredness, headache, muscle or body aches, chills or shivering, and shortness of breath. 3. Positive test for SARS-CoV-2 in upper respiratory swab on the day of dosing (rapid antigen test). 4. Understand and agree to comply with the planned study procedures. 5. The patient or legally authorized representative give signed informed consent.
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria are not eligible for inclusion in this study. 1. Requiring hospitalization at time of screening, or at time of study drug administration. 2. Oxygen saturation (SpO2) = 30 per minute, and heart rate >= 125 per minute. In India, patients with a respiratory rate >= 24 per minute or with an oxygen saturation 3. Known allergies to any of the components used in the formulation of the ensovibep or placebo. 4. Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides SARS-CoV-2) that in the opinion of the investigator could constitute a risk when taking intervention. 5. Any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study. 6. Any co-morbidity requiring surgery within 7 days of dosing, or that is considered life-threatening within 29 days of dosing. 7. Prior or concurrent use of any medication for treatment of COVID-19, including antiviral agents, convalescent serum, or anti-viral antibodies. Purely symptomatic therapies (e.g., over-the-counter [OTC] cough medications, acetaminophen, and nonsteroidal antiinflammatory drugs [NSAIDs]) are permitted. Prior vaccination for COVID-19 is permitted. 8. Are concurrently enrolled or were enrolled within the last 30 days or within 5 half-lives (whichever is longer) in any other type of medical research judged not to be scientifically or medically compatible with this study. 9. Are pregnant or breast feeding. 10. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception at the time of dosing and for 11 weeks after dosing of study drug. Highly effective contraception methods include: a. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (i.e., calendar, ovulation, symptothermal, and postovulation methods) and withdrawal are not acceptable methods of contraception. b.Female sterilization (have had bilateral surgical oophorectomy [with or without hysterectomy], total hysterectomy, or bilateral tubal ligation at least 6 weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment. c. Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that patient. d. use of oral, injected or implanted hormonal methods of contraception or placement of an IUD or IUS or other forms of hormonal contraception that have comparable efficacy (failure rate 1%) for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment. if local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form. Comorbidities defining clinically vulnerable patients (with
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part Aâ?¢To assess the effect of ensovibep, compared to placebo, in reducing SARS-CoV-2 viral load through Day 8. Part B â?¢To demonstrate superiority of ensovibep, compared to placebo, in reducing the occurrence of hospitalizations (â?¥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29Timepoint: Part A Endpoint: Time-weighted change from baseline (measured at Day 3, Day 5, and Day 8) in log10 SARS-CoV-2 viral load in nasopharyngeal swabs through Day 8. Part B Endpoint: Proportion of patients experiencing hospitalizations (â?¥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29 | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ To assess the effect of ensovibep, compared to placebo, in reducing COVID-19 symptoms up to Day 29Timepoint: Time to sustained clinical recovery, defined as (a) all symptoms from the modified FDA COVID-19 symptom list scored as moderate or severe at baseline are subsequently scored as mild or absent, AND (b) all symptoms from the modified FDA COVID-19 symptom list scored as mild or absent at baseline are subsequently scored as absent, with no subsequent worsening up to Day 29.;â?¢ To assess the effect of ensovibep, compared to placebo, in reducing SARS-CoV-2 viral load through Day 8.Timepoint: Change from baseline in log10 SARS-CoV-2 viral load in nasopharyngeal swabs at Day 3, Day 5, and Day 8 â?¢ To assess the effect of ensovibep, compared to placebo, in reducing COVID-19 symptoms up to Day 29 ;â?¢ To assess the effect of ensovibep, compared to placebo, in reducing the occurrence of hospitalizations (â?¥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29.Timepoint: Proportion of patients experiencing hospitalizations (â?¥ 24 hours of acute care) and/or emergency room visits related to COVID-19 or death from any cause up to Day 29.;â?¢ To evaluate the immunogenicity of ensovibep during the study and its clinical relevance (pharmacokinetic, efficacy and safety).Timepoint: Proportion of patients exhibiting treatment-emergent ADAs (TE-ADA) over time.;â?¢ To characterize the pharmacokinetics (PK) of ensovibep.Timepoint: Free and total ensovibep concentration in serum and calculated PK parameters.;â?¢ To evaluate safety and tolerability of ensovibep.Timepoint: Proportion of patients up to end of study with: a. Serious adverse events (SAEs), including death from any cause b. AEs of Special Interest (AESIs), including infusion-related reactions (IRRs) CTCAE grade 2 or higher 2. Vital signs 3. Clinical laboratory measurements.;â?¢To evaluate safety and tolerability of ensovibepTimepoint: Proportion of p | — |
Countries
Brazil, Czech Republic, Hungary, India, Indonesia, Kenya, Netherlands, Poland, South Africa, United States of America
Contacts
Public ContactSuneela Thatte
IQVIA RDS (India) Private Limited
Outcome results
None listed